376 related articles for article (PubMed ID: 12555220)
1. Successful engraftment and stable full donor chimerism after myeloablation with thiotepa, fludarabine, and melphalan and CD34-selected peripheral allogeneic stem cell transplantation in hemophagocytic lymphohistiocytosis.
Cesaro S; Gazzola MV; Marson P; Calore E; Caenazzo L; Destro R; De Silvestro G; Varotto S; Pillon M; Zanesco L; Messina C
Am J Hematol; 2003 Feb; 72(2):143-6. PubMed ID: 12555220
[TBL] [Abstract][Full Text] [Related]
2. Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant.
Devine SM; Sanborn R; Jessop E; Stock W; Huml M; Peace D; Wickrema A; Yassine M; Amin K; Thomason D; Chen YH; Devine H; Maningo M; van Besien K
Bone Marrow Transplant; 2001 Sep; 28(6):557-62. PubMed ID: 11607768
[TBL] [Abstract][Full Text] [Related]
3. Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma.
Giralt S; Aleman A; Anagnostopoulos A; Weber D; Khouri I; Anderlini P; Molldrem J; Ueno NT; Donato M; Korbling M; Gajewski J; Alexanian R; Champlin R
Bone Marrow Transplant; 2002 Sep; 30(6):367-73. PubMed ID: 12235521
[TBL] [Abstract][Full Text] [Related]
4. Transplantation of allogeneic CD34-selected stem cells after fludarabine-based conditioning regimen for children with mucopolysaccharidosis 1H (M. Hurler).
Grigull L; Beilken A; Schrappe M; Das A; Luecke T; Sander A; Stanulla M; Rehe K; Sauer M; Schmid H; Welte K; Lukacs Z; Gal A; Sykora KW
Bone Marrow Transplant; 2005 Feb; 35(3):265-9. PubMed ID: 15580280
[TBL] [Abstract][Full Text] [Related]
5. Rapid achievement of complete donor chimerism and low regimen-related toxicity after reduced conditioning with fludarabine, carmustine, melphalan and allogeneic transplantation.
Wäsch R; Reisser S; Hahn J; Bertz H; Engelhardt M; Kunzmann R; Veelken H; Holler E; Finke J
Bone Marrow Transplant; 2000 Aug; 26(3):243-50. PubMed ID: 10967561
[TBL] [Abstract][Full Text] [Related]
6. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update.
Bethge WA; Faul C; Bornhäuser M; Stuhler G; Beelen DW; Lang P; Stelljes M; Vogel W; Hägele M; Handgretinger R; Kanz L
Blood Cells Mol Dis; 2008; 40(1):13-9. PubMed ID: 17869547
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies.
Pedrazzoli P; Da Prada GA; Giorgiani G; Schiavo R; Zambelli A; Giraldi E; Landonio G; Locatelli F; Siena S; Della Cuna GR
Cancer; 2002 May; 94(9):2409-15. PubMed ID: 12015766
[TBL] [Abstract][Full Text] [Related]
8. Engraftment kinetics and hematopoietic chimerism after reduced-intensity conditioning with fludarabine and treosulfan before allogeneic stem cell transplantation.
Blau IW; Schmidt-Hieber M; Leschinger N; Göldner H; Knauf W; Hopfenmüller W; Thiel E; Blau O
Ann Hematol; 2007 Aug; 86(8):583-9. PubMed ID: 17468869
[TBL] [Abstract][Full Text] [Related]
9. Reduced-intensity conditioning regimen with thiotepa and fludarabine followed by allogeneic blood stem cell transplantation in haematological malignancies.
Alessandrino EP; Bernasconi P; Colombo AA; Caldera D; Malcovati L; Troletti D; Vanelli L; Varettoni M; Montanari F; Lazzarino M
Bone Marrow Transplant; 2004 Dec; 34(12):1039-45. PubMed ID: 15516936
[TBL] [Abstract][Full Text] [Related]
10. Fludarabine, cyclophosphamide and horse antithymocyte globulin conditioning regimen for allogeneic peripheral blood stem cell transplantation performed in non-HEPA filter rooms for multiply transfused patients with severe aplastic anemia.
Kumar R; Prem S; Mahapatra M; Seth T; Chowdhary DR; Mishra P; Pillai L; Narendra AM; Mehra NK; Saxena R; Choudhry VP
Bone Marrow Transplant; 2006 Apr; 37(8):745-9. PubMed ID: 16518427
[TBL] [Abstract][Full Text] [Related]
11. Comparable kinetics of myeloablation between fludarabine/full-dose busulfan and fludarabine/melphalan conditioning regimens in allogeneic peripheral blood stem cell transplantation.
Chunduri S; Dobogai LC; Peace D; Saunthararajah Y; Chen HY; Mahmud N; Quigley J; Hoffman R; Jessop E; Beri R; Rondelli D
Bone Marrow Transplant; 2006 Oct; 38(7):477-82. PubMed ID: 16980995
[TBL] [Abstract][Full Text] [Related]
12. Successful father-to-son stem cell transplantation in a child with hemophagocytic lymphohistiocytosis using a reduced-intensity conditioning regimen.
Gonzalez-Llano O; Jaime-Pérez J; Cantu-Rodríguez O; Mancias-Guerra C; Gutierrez-Aguirre H; Herrera-Garza J; Gomez-Almaguer D
Eur J Haematol; 2006 Oct; 77(4):341-4. PubMed ID: 16856932
[TBL] [Abstract][Full Text] [Related]
13. Reduced intensity conditioning regimen followed by glycosylated G-CSF mobilized PBSCT in patients with solid tumors and malignant lymphomas.
Castagna L; Bertuzzi A; Nozza A; Siracusano L; Balzarotti M; Magagnoli M; Sarina B; Timofeeva I; Sinnone M; Grimoldi MG; Farè M; Santoro A
Bone Marrow Transplant; 2002 Aug; 30(4):207-14. PubMed ID: 12203136
[TBL] [Abstract][Full Text] [Related]
14. Fludarabine-based reduced-intensity conditioning regimen for hematopoietic stem cell transplantation in primary hemophagocytic lymphohistiocytosis.
Hamidieh AA; Pourpak Z; Hashemi S; Yari K; Fazlollahi MR; Movahedi M; Behfar M; Moin M; Ghavamzadeh A
Eur J Haematol; 2014 Apr; 92(4):331-6. PubMed ID: 24330187
[TBL] [Abstract][Full Text] [Related]
15. Safety and outcome after fludarabine-thiotepa-TBI conditioning for allogeneic transplantation: a prospective study of 30 patients with hematologic malignancies.
van Besien K; Devine S; Wickrema A; Jessop E; Amin K; Yassine M; Maynard V; Stock W; Peace D; Ravandi F; Chen YH; Cheung T; Vijayakumar S; Hoffman R; Sosman J
Bone Marrow Transplant; 2003 Jul; 32(1):9-13. PubMed ID: 12815472
[TBL] [Abstract][Full Text] [Related]
16. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning.
Ogawa H; Ikegame K; Yoshihara S; Kawakami M; Fujioka T; Masuda T; Taniguchi Y; Hasei H; Kaida K; Inoue T; Kim EH; Kawase I
Biol Blood Marrow Transplant; 2006 Oct; 12(10):1073-84. PubMed ID: 17084371
[TBL] [Abstract][Full Text] [Related]
17. [Comparison of conditioning regimens containing or no fludarabine in nonmyeloablative allogeneic peripheral blood stem cell transplantation].
Guo M; Yu CL; Wang DH; Qiao JH; Sun WJ; Shi BF; Zhang S; Sun QY; Yao B; Ai HS
Zhonghua Xue Ye Xue Za Zhi; 2003 Aug; 24(8):413-5. PubMed ID: 14642178
[TBL] [Abstract][Full Text] [Related]
18. Successful unrelated mismatched cord blood transplantation in a child with malignant infantile osteopetrosis.
Jaing TH; Hou JW; Chen SH; Huang IA; Wang CJ; Lee WI
Pediatr Transplant; 2006 Aug; 10(5):629-31. PubMed ID: 16857002
[TBL] [Abstract][Full Text] [Related]
19. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
20. High-dose therapy and autologous peripheral blood stem cells transplantation followed by a very low reduced intensity regimen with fludarabine + cyclophosphamide and allograft improve complete remission rate in de novo multiple myeloma patients.
Martino M; Console G; Irrera G; Praticò G; Stelitano C; Callea V; Morabito F; Quartarone E; Musolino C; Piro E; Brugiatelli M; Iacopino P
Am J Hematol; 2006 Dec; 81(12):973-8. PubMed ID: 16888786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]